Cutera, Inc. (NASDAQ: CUTR) is a medical device company that designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. Today Cutera, Inc. is up over 4.4%. The company recently announced that it expects its revenues in the third quarter of 2018 to be approximately $40 million, or mid-single digit percentage growth over the third quarter of 2017. Based on this, the Company is revising full year 2018 revenue guidance to $165 million to $170 million, from $178 million to $181 million. Even with this news, the stock remains positive today.
Seres Therapeutics, Inc. (NASDAQ: MCRB) is up today about 1.5% around noon today. Seres Therapeutics, Inc. is a microbiome therapeutics platform company, engaging in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiple recurrent Clostridium difficile infection (CDI). The company announced it will present new data for SER-109, a microbiome candidate in development, at the IDWeek 2018 conference that was held from October 3-7 in San Francisco, CA. The findings, highlighted in two presentations, provide support for SER-109 as a potential new treatment option for individuals suffering from recurrent C. difficile infection. The company will also host a symposium on the development on novel microbiome therapeutics for C. difficile infection. “Additional SER-109 data provides valuable information about the potential mechanism of action of microbiome therapeutics, an emerging new field of medicine. Our results provide additional evidence supporting the continued development of SER-109 in patients with recurrent C. difficile infection. In addition, these new data suggest that SER-109 may have important broader public health benefits by reducing the spread of antibiotic resistance,” said Matthew Henn, Ph.D., Executive Vice President, Microbiome Research and Development at Seres Therapeutics.
Calithera Biosciences, Inc. (NASDAQ: CALA) is up over 1% today at noon. Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focusing on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company recently announced two new clinical trial collaborations to evaluate Pfizer’s palbociclib, also known as IBRANCE®, and the investigational dual-mechanism poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib, each in combination with Calithera’s glutaminase inhibitor CB-839. As part of the collaboration, Pfizer will provide palbociclib and talazoparib, as well as financial support. The ENTRATA trial, a randomized double-blind placebo-controlled study of late line patients, will enroll approximately 66 patients to receive either everolimus and CB-839 or everolimus alone. Topline results are expected in 2019.